scholarly journals Coexistence of Multiple Sclerosis and Alzheimer Disease Pathology: A Case Series

2021 ◽  
Vol 11 (3-4) ◽  
pp. 60-67
Author(s):  
Pauline Luczynski ◽  
Cornelia Laule ◽  
Ging-Yuek Robin Hsiung ◽  
G.R. Wayne Moore ◽  
Helen Tremlett
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer Disease ◽  
Case Series ◽  
Alzheimer Disease Pathology

scholarly journals COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: first national case series.

2021 ◽  
pp. 103049
Author(s):  
Geraldine Luetic ◽  
María L. Menichini ◽  
Marcos Burgos ◽  
Ricardo Alonso ◽  
Edgar Carnero Contentti ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Series ◽  
Multiple Sclerosis Patients

Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination

2021 ◽  
pp. 135245852199143
Author(s):  
Elsa Mhanna ◽  
Agathe Nouchi ◽  
Céline Louapre ◽  
Raphael De Paz ◽  
Olivier Heinzlef ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Case Series ◽  
Good Tolerance ◽  
Prevalence Studies ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Hpv Screening

Few cases of human papillomavirus (HPV) diseases have been reported in multiple sclerosis (MS) patients treated with fingolimod. We describe a case series of 16 MS patients (11 women, 5 men) developing HPV lesions after the onset of fingolimod, without previous HPV history. Fingolimod had to be discontinued in six patients. Six patients received vaccination for HPV, with good tolerance. Our report highlights that systematic HPV screening and discussion about HPV vaccination before fingolimod onset are crucial. In case of occurrence of HPV lesions during fingolimod treatment, a comprehensive workup of HPV disease is necessary, with discussion of HPV vaccination to prevent secondary lesions. Prevalence studies of HPV lesions are needed in MS patients with the different disease-modifying therapies.

scholarly journals Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

2021 ◽  
Author(s):  
Ilkka Rauma ◽  
Tiina Mustonen ◽  
Juha Matti Seppä ◽  
Maritta Ukkonen ◽  
Marianne Männikkö ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Case Series ◽  
Retrospective Case ◽  
Serious Adverse Events ◽  
Highly Active ◽  
Disease Modifying Therapy ◽  
Case Series Study ◽  
Multiple Sclerosis Patients

Abstract Background Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Results Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 months and exceeded 24 months in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1–3, respectively. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. Conclusions SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.

Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS

2021 ◽  
Vol 48 ◽  
pp. 102699
Author(s):  
Joseph V. Villarreal ◽  
Maria J. Abraham ◽  
Joanne Allieza G. Acevedo ◽  
Prashant K. Rai ◽  
Neeharika Thottempudi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Series ◽  
Tumefactive Multiple Sclerosis

scholarly journals The effect of functional limitations and fatigue on the quality of life in people with multiple sclerosis

2009 ◽  
Vol 67 (3b) ◽  
pp. 812-817 ◽  
Author(s):  
Leandro Alberto Calazans Nogueira ◽  
Felipe Resende Nóbrega ◽  
Kátia Nogueira Lopes ◽  
Luiz Claudio Santos Thuler ◽  
Regina Maria Papais Alvarenga
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Functional Limitations ◽  
Case Series ◽  
Lower Limbs ◽  
Case Series Study ◽  
Modified Ashworth Scale ◽  
Mild Disability ◽  
Fatigue Severity

The purpose of this study was to determine the effect of functional limitations and fatigue on the quality of life (QoL) in people with multiple sclerosis (MS). A descriptive case series study at Lagoa Hospital - Rio de Janeiro, Brazil was carried. The main outcome measurements were demographic variables, QoL (SF-36 v.1), disability (EDSS), motor function of the upper limb (Box & Blocks test), Tone (Modified Ashworth Scale), gait (Hauser ambulatory index) and fatigue (Fatigue Severity Scale). Sixty one patients fulfilled the study criteria. The mean age of patients was 39 years and 74% of patients were female. The most of cases presented mild disability (EDSS<3.5). A decrease was found in all domains of QoL. It was found association between physical functioning and the variables of EDSS, fatigue, lower limb tone and gait. Gait, disability, hypertonia of the lower limbs and fatigue negatively affected QoL in people with MS.

Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience

2006 ◽  
Vol 113 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Panteleimon Giannakopoulos ◽  
Gabriel Gold ◽  
Enikö Kövari ◽  
Armin von Gunten ◽  
Anouk Imhof ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Aging Brain ◽  
Vascular Burden ◽  
Alzheimer Disease Pathology

scholarly journals Blood Pressure's Role in Alzheimer Disease Pathology

2018 ◽  
Vol 26 (1) ◽  
pp. 23-24 ◽  
Author(s):  
Timothy M. Hughes ◽  
Samuel N. Lockhart ◽  
Stephen F. Smagula
Keyword(s):  
Alzheimer Disease ◽  
Alzheimer Disease Pathology

scholarly journals Original article Clinical and neuroimaging correlation of movement disorders in multiple sclerosis: case series and review of the literature

2014 ◽  
Vol 1 ◽  
pp. 92-100 ◽  
Author(s):  
Anna Potulska-Chromik ◽  
Monika Rudzinska ◽  
Monika Nojszewska ◽  
Aleksandra Podlecka-Piętowska ◽  
Andrzej Szczudlik ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Movement Disorders ◽  
Case Series ◽  
Review Of The Literature ◽  
Multiple Sclerosis Case
Sign in / Sign up

Export Citation Format

Share Document